Following a full submission
AWMSG advice |
|||
| Status: Recommended | |||
Lisdexamfetamine dimesylate (Elvanse®) is recommended as an option for use within NHS Wales as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (ADHD) in children aged six years of age and over when response to previous methylphenidate treatment is considered clinically inadequate. Treatment must be under the supervision of a specialist in childhood and/or adolescent behavioural disorders. |
|||
|
|||
Medicine details |
|||
| Medicine name | lisdexamfetamine dimesylate (Elvanse®) | ||
| Formulation | 30 mg capsule, 50 mg capsule and 70 mg capsule | ||
| Reference number | 188 | ||
| Indication | As part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (ADHD) in children aged 6 years of age and over when response to previous methylphenidate treatment is considered clinically inadequate. Treatment must be under the supervision of a specialist in childhood and/or adolescent behavioural disorders |
||
| Company | Shire Pharmaceuticals Ltd | ||
| BNF chapter | Central nervous system | ||
| Submission type | Full | ||
| Status | Recommended | ||
| Advice number | 2813 | ||
| NMG meeting date | 11/09/2013 | ||
| AWMSG meeting date | 16/10/2013 | ||
| Ratification by Welsh Government | 02/12/2013 | ||
| Date of issue | 03/12/2013 | ||
| Date of last review | 01/12/2016 | ||